Jefferies Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
Jefferies has initiated coverage on EyePoint Pharmaceuticals with a Buy rating and set a price target of $15.
August 28, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has initiated coverage on EyePoint Pharmaceuticals with a Buy rating and a price target of $15, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a reputable firm like Jefferies is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100